Where
you are...

Guideline Resource Info & Algorithm
................................... |
| |
| Downloads
Introduction [PDF]
2012 Update (not incorporated) [PDF]
Guideline Resource Information & Algorithm [PDF]
Information for Patients & Clinicians [PDF]
The Science: Treatment [PDF]
The Science: Diagnosis [PDF]
The Science: Communications [PDF]
Implementation Tips [PDF]
Impact Assessment Template [Excel]
|
| ...................................
Return to
Delfini Main Menu
Delfini
SERVICES
We
offer a wide
range of supportive
services with the ultimate goal of increasing health
care organizations’ and clinicians’ abilities to
provide high quality, evidence-based care and
to improve medical decision-making for organizations,
leaders, teams, clinicians and patients.
Delfini
About Our Work 
Resources
at —

|
BOX
A
Colon cancer screening, other screening issues and routine testing
of patients are not covered in this guideline, nor are patients meeting
these criteria: GUIDELINE
EXCLUSIONSPatients with these alarm symptoms, signs, diagnoses
require individual management (2):
- Age: Onset age 50
or older
- Any change in progression or in expected pattern of symptoms
- Unintended weight loss >5-10 lbs.
- Anorexia
- Vomiting
- GI bleeding
- Nocturnal symptoms
- Fever
- Any signs of infection
- Other diseases of the colon (e.g., colitis)
- Anemia
- Any abnormal findings upon exam
NOTE
1 |
|
“EXPLICIT" EVIDENCE-BASED CLINICAL
PRACTICE GUIDELINE RESOURCE KIT
Irritable Bowel Syndrome (IBS)
March 2003; FDA Addendum 4/04; Herbal Preparations 07/06; ROME
III Diagnostic Criteria 06/09; 01/2012:
Update—Not incorporated, only available as separate document—see Downloads
NOTE: 01/2012:
Update—Not incorporated, only available as separate document—see Downloads
Legal
Information & Disclaimers
These materials are not meant to replace the clinical judgment of any
health care professional or establish a standard of care. The information
contained in this document may not be appropriate for use in all circumstances.
Decisions to utilize this information must be made by consumers and health
care professionals in light of individual circumstances.
Before prescribing any medication, review full prescribing information
such as from the Physicians Desk Reference, DrugStore.Com or other source.
Delfini
Group, LLC, MAKES AND USER RECEIVES NO WARRANTY EXPRESS OR IMPLIED ABOUT
THIS WORK AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE ARE EXPRESSLY EXCLUDED
|
| GUIDELINE
RESOURCE INFORMATION & ALGORITHM SECTION
CONTENTS
NOTE 01/2012: Update—Not incorporated, only available as separate document—see Downloads
Treatment Information
Suggestions for
Using • Algorithm • Key
Points • Details
of Treatment Options [PDF]
Algorithm Notes =
IBS Definition & Description • Criteria
for Diagnosis • Establishing
Rapport • Diagnostic
Testing
Science
Scientific References
• Delfini
Evidence
& Usability Scale — (Use BACK to
return from the scale)
About the Guideline
Guideline Documentation
|
GUIDELINE RESOURCE INFORMATION
Suggestions for Using
The following guideline
materials (including the algorithm, key points, notes and associated
information and decision-aids) were designed primarily for primary
care physicians and other clinicians who diagnose and manage IBS
in adult patients.
These materials may
also be useful to professionals who plan and implement clinical
quality improvement projects.
It should be emphasized
that although the materials may be useful “as is,” we
recommend that each organization create information and decision
aids that meet local needs. |

IRRITABLE
BOWEL SYNDROME (IBS) GUIDELINE ALGORITHM |
|
ADULTS
WITH TYPICAL IBS SYMPTOMS (and without GUIDELINE EXCLUSIONS
- BOX A):
- IBS
Definition: Abdominal discomfort associated with
altered bowel habits.
- IBS
Diagnosis Criteria: Symptom-based criteria for IBS
(Rome III Criteria) – Recurrent abdominal
pain or discomfort at least 3 days per month in
the last 3 months associated with 2 or more of the
following
1. Improvement with defecation
2. Onset associated with a change in frequency of
stool
3. Onset associated with a change in form (appearance)
of stool
- Criteria
must be fulfilled for the last 3 months with symptom
onset at least 6 months prior to diagnosis.
- Discomfort
is defined as an uncomfortable sensation not described
as pain. Pain or discomfort frequency is of at least
2 days a week during screening evaluation for subject
eligibility for research studies.
-
(23) Longstreth GF, Thompson WG, Chey WD, Houghton
LA, Mearin F, Spiller RC. Functional bowel disorders.
Gastroenterology. 2006 Apr;130(5):1480-91.PMID:
16678561. [Note: Print version of the IBS
Guideline Resource Information & Algorithm
refers to Rome II criteria in this place in
the algorithm, but lists all Rome Criteria on
page 9)
NOTE
1 |
- Perform
hematocrit to rule out anemia. Other routine diagnostic
testing (e.g., thyroid function tests, stool tests,
colonic visualization) may not be required in the
work-up for IBS (11)
- For
other diagnostic tests see NOTE
2
|
| TREATMENT
OF IBS
- Should
be based on the type and severity of symptoms.
- There
is insufficient evidence to prioritize treatment
strategies.
- Patients
should be provided with information about the condition
along with self-care options and physician-directed
options.
- Options
include change in diet, over-the-counter preparations,
prescription medications and behavioral interventions.
|

DELFINI
INFORMATION QUALITY RATINGS
Grade
A - Useful Scientific Evidence B
- Possibly Useful U
- Uncertain Usefulness
|
| Treatment
Options for IBS |
Abdominal
Pain |
Constipation |
Diarrhea |
Gas
&
Bloating |
| Dietary
Change |
|
|
|
|
Herbal
Preparations
STW 5 (9 herbs sold under the name IberogastAA, Steigerwald
Arzneimittelwerk GmbH, Darmstadt, Germany; distributed
in the United States by Enzymatic Therapy, Green Bay,
WI [independent health food stores] and PhytoPharmica,
Green Bay, WI [pharmacies and healthcare professionals]).
STW 5 contains bitter candytuft plant (a.k.a. clown’s
mustard; Iberis amara L., Brassicaceae), German chamomile
flower (Matricaria recutita L., Asteraceae), peppermint
leaves (Mentha x piperita L., Lamiaceae), caraway
fruit (Carum carvi L., Apiaceae), licorice root (Glycyrrhiza
glabra L., Fabaceae), lemon balm leaves (Melissa officinalis
L., Lamiaceae), celandine herb (i.e., aerial parts
of Chelidonium majus L., Papaveraceae), angelica root
and rhizome (Angelica archangelica L., Apiaceae),
and milk thistle fruit (Silybum marianum [L.] Gaertn.
Asteraceae). |
 |
|
|
|
Bulking
Agents (Bulking Agents (IBS symptoms may initially
worsen)
Psyllium
Wheat bran
Corn fiber
Calcium polycarbophil
Ispaghula husk
|
|
|
|
|
Antispasmodics
(e.g. anticholinergics)
Dicyclomine
Hyoscyamine
|
|
|
|
|
Anti-diarrheals
Imodium (loperamide)
Lomotil (diphenoxylate hydrochloride 2.5 mg with atropine
sulfate 0.025mg)
|
|
|
Range
to |
|
| Gas-X,
Mylicon (simethicone) |
|
|
|
|
Tricyclic
Antidepressants, (TCAs) e.g. –
Nortriptyline (e.g., Pamelor)
Desipramine (e.g., Norpramin)
Amitriptyline (e.g., Elavil)
Doxepin (e.g., Sinequan)
|
|
Caution
is advised when using TCAs in IBS patients with
constipation |
|
|
SSRIs
(selective serotonin reuptake inhibitors)
e.g. –
Fluoxetine (e.g., Prozac)
Paroxetine (e.g., Paxil)
|
|
|
|
|
Serotonin
Receptor Antagonists for Diarrhea
Lotronex (alosetron)
|
(urgency)
See
cautions.
|
|
|
|
| Behavioral
Health Interventions |
Grade
B for certain individual symptoms |
|
|
DETAILS
ABOUT TREATMENT OPTIONS
For a complete listing of treatment options and for details about specific
treatments, go to the accompanying Delfini
Information & Decision Aid for Adult Patients and Clinicians
[PDF].
KEY
POINTS ACCOMPANYING ALGORITHM
| a.
Irritable Bowel Syndrome (IBS) is defined as “abdominal discomfort
associated with altered bowel habits” (2).
IBS is characterized by chronic and/or recurrent symptoms which may
be in combination: abdominal pain, discomfort, altered bowel habits,
episodes of diarrhea and/or constipation.
b. IBS is a common
condition with a prevalence of 10%-15% in North America.
c. There is good scientific
evidence that physicians who develop good rapport, based on positive
engagements, with IBS patients, and who provide relevant, valid
and, when possible, quantitative information about management options
are likely to improve patient health outcomes (8,
9, 10).
d. There is insufficient
evidence to conclude that, beyond history and physical examination,
any diagnostic testing (e.g., blood tests, stool tests, radiological
or endoscopic interventions) improves patient health outcomes in
patients with IBS (11).
e. In managing IBS,
patients should be provided with information about the condition
along with self-care options and physician-directed options. Options
include change in diet, over-the-counter preparations, prescription
medications and behavioral interventions. The evidence on these
options varies widely.
f. Alosetron
has been associated with some serious adverse events, some fatal.
Be sure to carefully review the most current prescribing information
on this agent.
Details about IBS management
and treatment options, along with the strength of the scientific
evidence for each option, are found in the accompanying Delfini
Information & Decision Aid for Adult Patients and Clinicians
[PDF].
|
|